MAP2K7 and melanoma: Translational data suggest that MEK and BRAF inhibition of oncogenic MAPK signaling can potentiate host antitumor immune response through its effects on T cells, including upregulation of melanoma antigen expression, upregulation of programmed death-ligand 1 (PD-L1) expression, and increased tumor T-cell infiltration (7–11).